Understanding Non-Small Cell Lung Cancer (NSCLC) and Its Treatment Options

By Anne-Marie Baird, Hossein Borghaei, Terri Conneran, Devika Das, Ticiana Leal, and Howard West

Non-small cell lung cancer (NSCLC) is one of the two primary types of lung cancer. Unfortunately, some lung cancers spread to other parts of the body before they are diagnosed. This type of cancer is called metastatic cancer. Fortunately, new lung cancer treatments are being developed that directly target the gene mutations that control how cancers grow and spread.

Driver Mutations and Their Role in NSCLC

The most crucial gene mutations in cancer are called driver mutations. In NSCLC, one of the key driver mutations is KRAS mutations, which can be used as targets for treatment. There are new treatments designed specifically for lung cancers with a KRAS mutation that are already available, and more are being developed.

Treating NSCLC: Understanding Clinical Trials

Treatments in development are tested in clinical trials, which have several different phases that people with cancer can participate in. This booklet aims to educate patients with NSCLC about their options, allowing them to have informed discussions with their doctors, nurses, and medical team about their cancer and its treatment.

Table of Contents:

• What is Non-Small Cell Lung Cancer?
• How Can Lung Cancer Develop?
• What is Metastatic NSCLC?
• More About Genes and Cancer
• Oncogenes and Cancer
• Driver Mutations and Biomarkers
• How Your Doctor Knows Your Cancer is KRAS-Positive
• More About KRAS
• What Does Having a KRAS-Positive Cancer Mean for Me?
• Talking to Your Doctor About Your Treatment
• About Clinical Trials and Research
• Finding Further Information and Support

This comprehensive guide is designed to empower patients with NSCLC, providing them with the knowledge and understanding they need to navigate their treatment options and make informed decisions about their care.